文章基本信息

标题：L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial
本地全文：下载
作者：Matthias Kraft ; Kathleen Kraft ; Simone Gärtner 等
期刊名称：Nutrition Journal
印刷版ISSN：1475-2891
电子版ISSN：1475-2891
出版年度：2012
卷号：11
期号：1
页码：52
DOI：10.1186/1475-2891-11-52
语种：English
出版社：BioMed Central
摘要：Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia. We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2,5 (SEM) kg. During treatment body-mass-index increased by 3,4 ± 1,4% under L-Carnitine and decreased (−1,5 ± 1,4%) in controls (p < 0,05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.). While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine.
关键词：Pancreatic adenocarcinoma ; L-Carnitine ; Quality of life ; Survival ; Cancer cachexia ; Fatique syndrome